We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+10.19%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$10.2B
AUM Growth
+$2.04B
(+25%)
Cap. Flow
+$1.34B
Cap. Flow
% of AUM
13.16%
Top 10 Holdings %
Top 10 Hldgs %
16.92%
Holding
1,109
New
201
Increased
523
Reduced
236
Closed
122
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$57.2M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$52.3M |
| 3 |
Micron Technology
MU
|
+$46M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$45.6M |
| 5 |
Apple
AAPL
|
+$41.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$76.7M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$62.9M |
| 3 |
NVR
NVR
|
+$49.7M |
| 4 |
AZPN
ASPEN TECHNOLOGY INC
AZPN
|
+$37.5M |
| 5 |
DFS
Discover Financial Services
DFS
|
+$35.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.58% |
| 2 | Financials | 15.64% |
| 3 | Healthcare | 14.3% |
| 4 | Consumer Discretionary | 12.01% |
| 5 | Industrials | 9.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
UNIFI
UFI
$117M
| $653K | 0.01% |
25,858
+12,858
| +99% | +$310K |
|
752
Protagonist Therapeutics
PTGX
$8.75B
| $647K | 0.01% |
91,831
+78,021
| +565% | +$775K |
|
753
Neuronetics
STIM
$120M
| $646K | 0.01% |
+143,946
| New | +$894K |
|
754
CNX Resources
CNX
$4.85B
| $640K | 0.01% |
+72,300
| New | +$564K |
|
|
APTX
755
DELISTED
Aptinyx Inc. Common Stock
APTX
| $639K | 0.01% |
186,831
+102,332
| +121% | +$352K |
|
756
Kiniksa Pharmaceuticals
KNSA
$4.83B
| $637K | 0.01% |
+57,627
| New | +$501K |
|
|
KDNY
757
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $622K | 0.01% |
105,468
+54,312
| +106% | +$295K |
|
758
Cyclerion Therapeutics
CYCN
$15.2M
| $615K | 0.01% |
11,302
+7,576
| +203% | +$707K |
|
759
SmartFinancial
SMBK
$855M
| $615K | 0.01% |
+26,020
| New | +$573K |
|
760
Digital Turbine
APPS
$1.02B
| $612K | 0.01% |
85,866
| – | – |
|
761
Forestar Group
FOR
$1.44B
| $607K | 0.01% |
29,104
+11,679
| +67% | +$228K |
|
762
Argan
AGX
$7.98B
| $602K | 0.01% |
+14,999
| New | +$577K |
|
763
Pfizer
PFE
$140B
| $601K | 0.01% |
+16,178
| New | +$576K |
|
764
Bridgewater Bancshares
BWB
$579M
| $589K | 0.01% |
+42,739
| New | +$542K |
|
765
Haemonetics
HAE
$3.58B
| $589K | 0.01% |
5,130
-1,730
| -25% | -$209K |
|
|
VMW
766
DELISTED
VMware, Inc
VMW
| $589K | 0.01% |
+3,878
| New | +$608K |
|
767
Kilroy Realty
KRC
$4.58B
| $571K | 0.01% |
+6,800
| New | +$555K |
|
768
AngioDynamics
ANGO
$562M
| $570K | 0.01% |
+35,597
| New | +$544K |
|
|
RVLP
769
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
| $570K | 0.01% |
81,565
+57,115
| +234% | +$305K |
|
|
ADMS
770
DELISTED
Adamas Pharmaceuticals
ADMS
| $568K | 0.01% |
149,979
+71,379
| +91% | +$342K |
|
|
ZNGA
771
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $561K | 0.01% |
91,600
-20,200
| -18% | -$125K |
|
|
CDTX
772
DELISTED
Cidara Therapeutics
CDTX
| $555K | 0.01% |
+7,230
| New | +$331K |
|
773
Public Storage
PSA
$60.2B
| $552K | 0.01% |
2,594
-210
| -7% | -$46.6K |
|
774
Atara Biotherapeutics
ATRA
$71.2M
| $545K | 0.01% |
+1,323
| New | +$456K |
|
|
TBNK
775
DELISTED
Territorial Bancorp Inc.
TBNK
| $544K | 0.01% |
17,592
+2,050
| +13% | +$62K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q4 2019 Portfolio in Review
As of Q4 2019, Jacobs Levy Equity Management held 1,109 positions worth $10.2B, up 25% from $8.15B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $1.34B of net new capital in Q4 2019, opening 201 new positions and adding to 523 existing holdings. Its largest new stake was Athene Holding Ltd. Class A Common Shares: 551,505 shares worth $25.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Qualcomm, an estimated $76.7M trimmed.
- Jacobs Levy Equity Management's largest Q4 2019 buy was Athene Holding Ltd. Class A Common Shares: 551,505 shares worth $25.9M.
- Jacobs Levy Equity Management added most to AbbVie in Q4 2019, an estimated $57.2M increase.
- Jacobs Levy Equity Management's biggest Q4 2019 reduction was Qualcomm, cutting an estimated $76.7M.
- Jacobs Levy Equity Management fully exited NVR in Q4 2019, selling an estimated $49.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $10.2B portfolio in Q4 2019.
- Jacobs Levy Equity Management opened 201 new positions and closed 122 in Q4 2019.
- Jacobs Levy Equity Management's portfolio value rose 25% quarter-over-quarter to $10.2B.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2019, filed 14 Feb 2020.